|
WO2020243119A1
|
|
Methods of altering cardiac remodeling using compounds that promote glucose oxidation
|
|
WO2020247213A1
|
|
Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinase
|
|
WO2020243120A1
|
|
Methods of treating fibrosis using compounds that promote glucose oxidation
|
|
WO2020190671A1
|
|
Methods of treating cancer using trimetazidine-based compounds
|
|
WO2020163188A1
|
|
Compositions containing n-acetylcysteine conjugated to a tca cycle intermediate
|
|
CA3113290A1
|
|
Compositions and methods for treating and preventing leber's hereditary optic neuropathy
|
|
WO2020081361A1
|
|
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
CA3113071A1
|
|
Tca cycle intermediates and methods of use thereof
|
|
US2019314319A1
|
|
Combination therapy
|
